InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (7 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
7
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Dier Mardi, Chief Financial Officer. Officer active across 5 companies, notably Adamas Pharmaceuticals Inc. Cumulatively, 14 filings have been published. Breakdown: 1 buy · 7 sells. Total volume traded: €1.5m. Activity tracked since 2 June 2021. The latest transaction was disclosed on 4 March 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Dier Mardi
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
5,215 shares0Common StockSEC:0001628280-26-015775:0
1,183 shares@ US$427.2124.1% of flowCommon StockSEC:0001628280-26-013394:0
4,173 shares@ US$251.6366.9% of flowCommon StockSEC:0001628280-25-055164:0
258 shares@ US$323.0417.1% of flowCommon StockSEC:0001628280-25-012369:0
3,784 shares0Common StockSEC:0001628280-25-011407:0
1,187 shares@ US$325.8982.9% of flowCommon StockSEC:0001628280-25-010508:0
5,556 shares@ US$18.00100.0% of flowCommon StockSEC:0001209191-23-028864:0
Canonical exit: 7 Aug 2023 (T+90)
1,629 shares@ US$40.169.1% of flowCommon StockSEC:0001209191-22-053884:0
3,484 shares@ US$38.2218.7% of flowCommon StockSEC:0001209191-22-053647:0
20,000 shares0Common StockSEC:0001209191-22-050670:0
534 shares@ US$66.626.5% of flowCommon StockSEC:0001209191-22-015833:0
3,477 shares@ US$82.7951.4% of flowCommon StockSEC:0001209191-21-060504:0
5,000 shares0Common StockSEC:0001328143-21-000056:0
13,750 sharesCommon StockSEC:0001209191-16-094212:0
14 of 14 declarations
About Dier Mardi
Dier Mardi is Chief Financial Officer and has reported 14 filings in total. Across the 14 sampled filings, the activity spans 2016-01-29 to 2026-03-06, with EUR 91,209 of buys and EUR 1,363,518 of sells, and the most frequent transaction type is Sale. The filings involve Madrigal Pharmaceuticals, INC., Ultragenyx Pharmaceutical Inc., ACELYRIN, Inc., Adamas Pharmaceuticals Inc and PORTOLA PHARMACEUTICALS INC.
